Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
暂无分享，去创建一个
W. Scheithauer | V. Heinemann | J. Holch | T. Decker | A. Kiani | C. Westphalen | S. Stintzing | F. Kullmann | L. Fischer von Weikersthal | M. Moehler | M. Michl | T. Heintges | C. Kahl | D. Modest | J. V. von Einem | I. Ricard | I. Jelas | U. Vehling‐Kaiser